Tina Guanting Qui (Qui pronunciation sounds like “chew”), MD, Ph.D., president/CEO of Ophthalmic Therapeutic Innovation LLC, built teams to lead pharmacology drug delivery innovation for glaucoma and retinal diseases for Glaxo Smith-Kline, Inotek, Sucampo and Astellas. She also was chief medical officer for BetaStem Therapeutics, an executive consultant for LambdaVision and Lineage Cell Therapeutics, and has led data-driven clinical investigations on diabetic retinopathy and age-related macular degeneration.